China
Cullgen Announces First-In-Human Dose in Phase I/II Trial of CG001419, a First-in-Class TRK Protein Degrader for Treatment of Cancer Patients
Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that it has initiated dosing with its orally bioavailable pan-TRK degrader, CG001419, in a Phase I/II clinical trial for patients with solid tumors.
Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development
Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that Dr. Francois Lebel, M.D., an experienced biopharmaceutical industry executive, has been appointed as Senior Vice President for preclinical and clinical development of the Group.
Qihan Biotech Appoints Naxin Yao to its Board of Directors
Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced today the appointment of Mr. Naxin Yao, as an independent director to its Board of Directors.
境外上市备案制第一家赴美国IPO获「备案通知书」，新骏羊绒服饰拟纳斯达克上市
Shanghai-based Majestic Ideal Holdings Limited is the first Chinese company to receive a green light from China's CSRS to be listed in the US, since the government agency published new rules for offshore listings on March 31.
Acceptance Of Clinical Trial Application For The Recbio’s Novel Adjuvanted Recombinant Shingles Vaccine REC610 In China And Overseas Clinical Trial Progress
Jiangsu Recbio Technology Co., Ltd. (the"Board") is pleased to announce that the Group has recently received the notice of acceptance (acceptance number: CXSL2300518) issued by National Medical Products Administration ("NMPA"), pursuant to which the clinical trial application for its self-developed novel adjuvanted recombinant shingles vaccine REC610 has been accepted.
WuXi Vaccines’ First Drug Substance Facility in China Released for GMP Manufacturing
WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced the successful GMP release of its CHO cell-based drug substance (DS) manufacturing facility located in Suzhou, China.
Singapore’s Mirxes to List in Hong Kong After Securing $50M in Series D Funding
Mirxes Holding Company Limited, a Singapore-headquartered biotech firm, announced Tuesday that it has filed listing application with The Stock Exchange of Hong Kong Limited after securing $50 million Series D funding.
Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today XERAVA® (eravacycline) has been successfully launched in China with its first prescription issued at Huashan Hospital affiliated to Fudan University.
LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis
Tarsus Pharmaceuticals (Tarsus) announced yesterday that the U.S. Food and Drug Administration (FDA) approved XDEMVY™ (lotlilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis.
Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its Aderamastat Phase 2 Study Results at the European Respiratory Society (ERS) International Congress 2023
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today that the company has been selected for a late-breaking oral presentation on the positive primary outcomes of its aderamastat (FP-025) Phase 2 proof-of-concept allergic asthma study at the European Respiratory Society (ERS) International Congress 2023 taking place in Milan, Italy from September 9-13, 2023.
